Radiopharm Theranostics Limited (RADX), a radiotherapeutics company, has a couple of clinical trial events lined up for this year.
This Australian clinical-stage company is developing radiopharmaceutical products for diagnostic and therapeutic applications in cancer treatment. Its pipeline includes 18F-RAD 101, a proprietary F18-tagged radiotracer for the detection and characterization of brain metastasis; 177Lu-labelled RAD204 for the treatment of PD-L1-expressing cancers; and 177Lu-labelled RAD202 for the treatment of HER2-expressing solid tumors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com